Is NMN the same as NAD+?

No. NMN is a precursor — a raw material your body converts into NAD+. NAD+ is the active molecule that powers cellular energy and repair. Think of NMN as the ingredient and NAD+ as the finished product. Researchers study NMN partly because NAD+ itself is hard to deliver orally without it breaking down first.[1]

What doses of NMN have been used in human clinical trials?

Published human trials have tested a range of doses. One randomized trial used 300 mg, 600 mg, and 900 mg per day for 60 days, finding blood NAD+ increases at all three levels with no safety issues.[5] Another study used 250 mg per day and observed improvements in muscle insulin sensitivity.[6] Doses vary by study design and population.

Why do NAD+ levels fall with age?

Research suggests that as we age, the enzymes that produce NAD+ become less active, while the enzymes that consume it stay busy or become more active. The result is a gradual drop in NAD+ concentration across tissues like muscle, skin, liver, and brain. This decline is one reason scientists are interested in precursors like NMN as a potential way to restore levels.[2]

Can I get NMN from food?

Yes, in small amounts. NMN is naturally present in vegetables, meat, and milk. It can also form as a metabolite when your body digests dietary NAD+. However, the amounts found in typical foods are far lower than the doses used in clinical research, which is why supplement forms became the focus of trials.[3]

NAD+ vs NMN: Research Dosing Comparison Guide

Two Names, Two Different Things

You have probably seen both NAD+ and NMN mentioned in the same breath. They are related, but they play different roles.

NAD+ stands for nicotinamide adenine dinucleotide. It is a molecule found inside every cell in your body. Think of it as a rechargeable battery — it carries electrons around to power hundreds of chemical reactions, including DNA repair and energy production.^[1]

NMN stands for nicotinamide mononucleotide. It is a precursor. That means your body takes NMN and builds it up into NAD+. It is one step earlier in the production line.^[1]

Here is the simple reason researchers study NMN: NAD+ levels in blood, muscle, skin, and brain appear to fall as we age. NMN is one way scientists are trying to nudge those levels back up.^[2]

A Quick Side-by-Side

What it is: NAD+ is the end-product coenzyme; NMN is a direct dietary precursor to NAD+.
Where it comes from: NAD+ is made inside your cells; NMN is found in small amounts in vegetables, meat, and milk — and can be taken as a supplement.^[3]
What research measures: NAD+ studies track cellular or blood NAD+ levels directly; NMN studies usually measure the rise in blood NAD+ after supplementation.^[5]
Animal data: Long-term NMN administration in mice improved energy metabolism, insulin sensitivity, and physical activity without obvious toxicity.^[4]
Human trial status: Multiple human trials for NMN have been completed; NAD+ itself is harder to deliver orally because it breaks down before cells can absorb it.^[2]

How Research Doses Are Set Up

Doses in published studies vary quite a bit, so it helps to know the range before you read a paper.

In a randomized, double-blind trial of 80 healthy middle-aged adults, participants took 300 mg, 600 mg, or 900 mg of NMN once a day for 60 days. Blood NAD+ levels rose significantly in all three groups compared to placebo. The 600 mg and 900 mg groups saw the highest increases. No safety problems were found at any dose.^[5]

A separate clinical study focused on prediabetic women who took 250 mg of NMN per day. Researchers found improvements in how well muscle cells responded to insulin — a result that pointed toward metabolic benefits rather than just a change in a lab number.^[6]

These numbers — 250 mg, 300 mg, 600 mg, 900 mg — are research doses used in controlled settings. They are not the same as a recommendation for personal use. The science is still developing, and study designs, populations, and endpoints differ widely.^[2]

Why the Pharmacokinetics Still Matter

Pharmacokinetics is just a fancy word for what happens to a substance after you take it — how it is absorbed, where it travels, and how fast it is used up.

Researchers still debate exactly how NMN gets into cells. Does it convert to NAD+ in the gut first? Does it enter cells directly? The answer may depend on which tissue you are looking at and which enzymes are present there.^[1] This is one reason you will see different dosing strategies across studies — scientists are still mapping the route.

For NAD+ itself, oral delivery is tricky. The molecule is large and gets broken down during digestion. That is precisely why precursors like NMN became a major research focus.^[3]

How to Choose What to Read

If you want to understand the foundational biology — what NAD+ does inside a cell, why it declines with age, and the full theoretical case for precursor therapy — start with the NAD+ research charts. The science there is deeper and older.

If you want to look at human trial data — doses tested, blood NAD+ changes, safety signals, and metabolic outcomes — head to the NMN research charts. That is where the most recent clinical evidence lives.

Not sure where to begin? Use the calculator to explore how study variables like body weight, dose, and trial duration relate to the numbers you see in published research. It is a useful orientation tool before diving into any specific paper.

The field is moving fast. New human trials are underway, and the picture will keep getting clearer.^[2] Reading the primary research — even at a high level — is the best way to stay grounded in what the evidence actually shows.

Sources

NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR. — Cell metabolism, 2018. PMID 29249689.
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. — Advances in nutrition (Bethesda, Md.), 2023. PMID 37619764.
NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. — Current nutrition reports, 2023. PMID 37273100.
Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. — Cell metabolism, 2016. PMID 28068222.
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. — GeroScience, 2023. PMID 36482258.
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. — Science (New York, N.Y.), 2021. PMID 33888596.

NAD+ vs NMN: Simple Comparison, Research Doses Explained